EA200701766A1 - ANTIBODIES AGAINST CANDIDA ANTIGENS - Google Patents

ANTIBODIES AGAINST CANDIDA ANTIGENS

Info

Publication number
EA200701766A1
EA200701766A1 EA200701766A EA200701766A EA200701766A1 EA 200701766 A1 EA200701766 A1 EA 200701766A1 EA 200701766 A EA200701766 A EA 200701766A EA 200701766 A EA200701766 A EA 200701766A EA 200701766 A1 EA200701766 A1 EA 200701766A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies against
against candida
candida antigens
antigens
domain antibodies
Prior art date
Application number
EA200701766A
Other languages
Russian (ru)
Inventor
Антонио Кассоне
Флавия Де Бернардис
Стивен Грант
Хайкьюн Лиу
Original Assignee
Домантис Лимитед
Антонио Кассоне
Флавия Де Бернардис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505489A external-priority patent/GB0505489D0/en
Priority claimed from GBGB0519883.3A external-priority patent/GB0519883D0/en
Application filed by Домантис Лимитед, Антонио Кассоне, Флавия Де Бернардис filed Critical Домантис Лимитед
Publication of EA200701766A1 publication Critical patent/EA200701766A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Предложены доменные антитела. В частности, доменные антитела (dAb), которые распознают признаки вирулентности Candida spp. и обеспечивают пассивную защиту против кандидоза.Domain antibodies are proposed. In particular, domain antibodies (dAb) that recognize the signs of virulence of Candida spp. and provide passive protection against candidiasis.

EA200701766A 2005-03-18 2006-03-10 ANTIBODIES AGAINST CANDIDA ANTIGENS EA200701766A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0505489A GB0505489D0 (en) 2005-03-18 2005-03-18 Antibodies
GBGB0519883.3A GB0519883D0 (en) 2005-09-29 2005-09-29 Antibodies
PCT/GB2006/000843 WO2006097689A2 (en) 2005-03-18 2006-03-10 Antibodies against candida antigens

Publications (1)

Publication Number Publication Date
EA200701766A1 true EA200701766A1 (en) 2008-04-28

Family

ID=36808786

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701766A EA200701766A1 (en) 2005-03-18 2006-03-10 ANTIBODIES AGAINST CANDIDA ANTIGENS

Country Status (12)

Country Link
US (1) US8092800B2 (en)
EP (1) EP1863845A2 (en)
JP (1) JP2008533115A (en)
KR (1) KR20080003351A (en)
AU (1) AU2006224438A1 (en)
CA (1) CA2601115A1 (en)
EA (1) EA200701766A1 (en)
IL (1) IL185781A0 (en)
MA (1) MA29394B1 (en)
MX (1) MX2007011356A (en)
NO (1) NO20074616L (en)
WO (1) WO2006097689A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601115A1 (en) 2005-03-18 2006-09-21 Domantis Limited Antibodies against candida antigens
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US20090081196A1 (en) * 2007-02-16 2009-03-26 Istituto Superiore Di Sanita Medicaments for fungal infections
US20110257373A1 (en) * 2008-10-21 2011-10-20 Rudolf Maria De Wildt Ligands that have binding specificity for dc-sign
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
JP2014515757A (en) * 2011-04-21 2014-07-03 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ Peptides and conjugate vaccines for fungal infections
CN107663239A (en) * 2016-12-28 2018-02-06 天津天锐生物科技有限公司 A kind of identification HLA A2/NLVPMVATV single domain antibody
CN112457405B (en) * 2018-09-27 2022-08-12 暨南大学 Anti-human EGFR nano antibody and application
WO2020130838A2 (en) * 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
CN112646035B (en) * 2020-12-25 2022-06-24 暨南大学 Affinity maturation binding protein of EGFR (epidermal growth factor receptor) and application

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419781B1 (en) 1999-02-01 2008-09-02 Planton Gmbh Human antibiotic proteins
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP1485130A4 (en) 2002-02-21 2006-11-22 Univ Duke Reagents and treatment methods for autoimmune diseases
ES2263984T3 (en) * 2002-06-28 2006-12-16 Domantis Limited DOUBLE-SPECIFIC LINKS WITH AN INCREASED SERIOUS MIDDLE LIFE.
JP2006520584A (en) * 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． Stabilized single domain antibody
US9028816B2 (en) * 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
JP2007528201A (en) * 2003-03-14 2007-10-11 ファルマシア・コーポレーション Antibody to IGF-I receptor for cancer treatment
CN1845938B (en) 2003-06-30 2010-05-26 杜门蒂斯有限公司 Polypeptides
WO2005097202A2 (en) 2004-04-06 2005-10-20 Affibody Ab Use of serum albumin binding peptides conjugates for the preparation of a medicament
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2601115A1 (en) 2005-03-18 2006-09-21 Domantis Limited Antibodies against candida antigens
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections

Also Published As

Publication number Publication date
EP1863845A2 (en) 2007-12-12
MA29394B1 (en) 2008-04-01
KR20080003351A (en) 2008-01-07
AU2006224438A1 (en) 2006-09-21
IL185781A0 (en) 2008-01-06
JP2008533115A (en) 2008-08-21
WO2006097689A2 (en) 2006-09-21
US20080193450A1 (en) 2008-08-14
US8092800B2 (en) 2012-01-10
NO20074616L (en) 2007-11-27
CA2601115A1 (en) 2006-09-21
WO2006097689A3 (en) 2007-03-15
MX2007011356A (en) 2008-03-10

Similar Documents

Publication Publication Date Title
EA200701766A1 (en) ANTIBODIES AGAINST CANDIDA ANTIGENS
CY1119102T1 (en) ANTIBODIES AND IMMUNITIES AND USERS
NO20085396L (en) Antibodies and immune conjugates, and uses thereof
ECSP088831A (en) ANTI-TAT226 ANTIBODIES AND IMMUNOCATE PLAYERS
CL2007003622A1 (en) Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
TW200732349A (en) Anti-OX40L antibodies and methods using same
NO20083891L (en) Anti-5T4 antibodies and uses thereof
NO20083127L (en) Methods and preparations for targeting polyubiquitin
EA200970210A1 (en) PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS
BRPI0510170A (en) muscarinic acetylcholine receptor antagonists
EA200702643A1 (en) TWEAK ANTIBODIES
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
CR10530A (en) ANTI-DLLA4 ANTIBODIES AND METHODS THAT USE THEM
DK2176296T3 (en) Anti-CD79B antibodies and immune conjugates and methods of use.
IS8026A (en) Antibodies against amyloids, combinations, methods and uses
WO2007136815A3 (en) Tagged microorganisms and methods of tagging
BRPI0506777A (en) muscarinic acetylcholine receptor antagonists
MY151051A (en) Vaccination against dengue virus infection
MX2009004881A (en) Agonist trkb antibodies and uses thereof.
AR063026A1 (en) ANTIBODIES DIRECTED AGAINST CCR5 AND THE USE OF THE SAME
AR059096A1 (en) ANTI-EFRINE ANTIBODIES -B2 AND METHODS USING THESE
MY150643A (en) Methods and compositions for targeting hepsin
WO2007126813A3 (en) Cross-reactive monoclonal antibodies recognizing als family proteins
FR2886307B1 (en) COEXTRUSION BINDER OF PE AND PP DILUTED COGREEES IN AN UN-GRAFTED PE.
FR2918664B1 (en) TRIFUNCTIONAL PEPTIDE PSEUDO REAGENT, USES THEREOF AND APPLICATIONS.